Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Tessera Therapeutics is a life sciences company founded by Flagship Pioneering. They are developing a new category of genetic medicine known as Gene Writing™ technology. This technology aims to overcome the limitations of existing gene editing and gene therapy approaches by efficiently writing therapeutic messages into the genome to treat and cure diseases. Tessera's platform has the potential to make precisely targeted and highly efficient changes to the genome, including inserting or deleting, and rewriting, genes of any length.
Primary hub for research and development, corporate operations, laboratory work, and strategic leadership in advancing Gene Writing technology.
State-of-the-art laboratory facilities, modern collaborative workspaces, and located within a thriving biotechnology and life sciences cluster near Boston/Cambridge.
An innovative, science-driven, and collaborative environment focused on pioneering genetic medicines. The culture emphasizes cutting-edge research, teamwork, and a strong mission to impact human health.
Serves as the central nervous system for Tessera's groundbreaking research, platform development, and efforts to bring Gene Writing therapies to patients.
Tessera Therapeutics is primarily focused on its research and development operations within the United States, with its main campus located in Somerville, Massachusetts. While their therapeutic ambitions and potential market reach are global, their physical office and laboratory presence is currently concentrated in the U.S. to foster close-knit collaboration for their pioneering Gene Writing platform.
100 South St
Somerville
Massachusetts
USA
Address: 100 South St (Main Campus)
This site serves as the core innovation and operational hub, strategically positioned within the Boston-area biotechnology ecosystem to leverage talent and collaborations.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Tessera Therapeutics' leadership includes:
Tessera Therapeutics has been backed by several prominent investors over the years, including:
Tessera Therapeutics has made several key executive appointments in the past 12 months to strengthen its leadership team, particularly in scientific, technological, financial, and regulatory domains. No major C-suite departures have been publicly announced during this period.
Discover the tools Tessera Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Tessera Therapeutics likely uses common professional email formats. The most probable format is [first_initial][last]@[domain] or [first].[last]@[domain].
[first_initial][last]@tessera.com
Format
jdoe@tessera.com
Example
90%
Success rate
Tessera Therapeutics Press Release • January 18, 2024
Tessera Therapeutics announced the appointment of Mary Rozenman, Ph.D., as Chief Financial Officer (CFO) and Chief Business Officer (CBO). Dr. Rozenman brings over 15 years of experience in biotech and pharma strategy, finance, and business development....more
Tessera Therapeutics Press Release • October 26, 2023
Tessera announced the appointment of Lin Guey, Ph.D., as Chief Technology Officer. Dr. Guey will be responsible for all aspects of technology development for Tessera's Gene Writing platform....more
Fierce Biotech • April 12, 2023
Tessera Therapeutics secured over $300 million in a Series C financing round. The funds will be used to advance its Gene Writing platform and move multiple RNA-based therapeutic programs toward clinical development....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Tessera Therapeutics, are just a search away.